Clinical applications and biosafety of human adult mesenchymal stem cells

Current Pharmaceutical Design

Volumn 18, Issue 13, 2012, Pages 1821-1845

  Mariani, E ^a,b   Facchini, A ^a,b  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Adipose derived stem cell; Adult; Biological characteristics; Biosafety; Bone marrow mesenchymal stem cell; Cell therapy; Clinical applications; Human

Indexed keywords

5' NUCLEOTIDASE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ALPHA1 INTEGRIN; ALPHA2 INTEGRIN; ALPHA3 INTEGRIN; ALPHA4 INTEGRIN; ALPHA5 INTEGRIN; BETA1 INTEGRIN; CD133 ANTIGEN; CD14 ANTIGEN; CD146 ANTIGEN; CD19 ANTIGEN; CD200 RECEPTOR; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD51 ANTIGEN; CD79 ANTIGEN; CD9 ANTIGEN; CELL SURFACE MARKER; CYTOKINE; ENDOGLIN; HERMES ANTIGEN; MICROSOMAL AMINOPEPTIDASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; REMESTEMCEL L; STEM CELL FACTOR RECEPTOR; THY 1 ANTIGEN; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE GRAFT VERSUS HOST DISEASE; ADAPTIVE IMMUNITY; AMYOTROPHIC LATERAL SCLEROSIS; ANUS FISTULA; ARTICLE; AUTOIMMUNE DISEASE; BIOSAFETY; BONE MARROW CELL; CARDIOVASCULAR DISEASE; CELL CULTURE; CELL DIFFERENTIATION; CELL LINEAGE; CELL MANIPULATION; CELL POPULATION; CELL REGENERATION; CHRONIC GRAFT VERSUS HOST DISEASE; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOLOGY; DIABETES MELLITUS; DONOR; EX VIVO STUDY; GASTROINTESTINAL DISEASE; GERM LAYER; GLIOBLASTOMA; HEART DISEASE; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; KAPOSI SARCOMA; LIMB ISCHEMIA; LIVER FAILURE; LUNG CARCINOMA; MELANOMA; MESENCHYMAL STEM CELL; MICROENVIRONMENT; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOARTHRITIS; OSTEOGENESIS IMPERFECTA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SERUM; SHY DRAGER SYNDROME; ULCERATIVE COLITIS;

ADULT; GRAFT VS HOST DISEASE; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; SAFETY;

EID: 84860121720     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799859666     Document Type: Article

References (394)

1. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968; 6: 230-247.
2. Caplan AI. Mesenchymal stem cells. J Orthop Res 1991; 9: 641-650.
3. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995; 16: 557-564.
4. Gronthos S, Zannettino AC, Hay SJ, et al. Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci 2003; 116: 1827-1835.
5. d'Ippolito G, Diabira S, Howard GA, Menei P, Roos BA, Schiller PC. Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci 2004; 117: 2971-2981.
6. Belema-Bedada F, Uchida S, Martire A, Kostin S, Braun T. Efficient homing of multipotent adult mesenchymal stem cells depends on FROUNT-mediated clustering of CCR2. Cell Stem Cell 2008; 2: 566-575.
7. Devine SM, Hoffman R. Role of mesenchymal stem cells in hematopoietic stem cell transplantation. Curr Opin Hematol 2000; 7: 358-363.
8. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006; 6: 93-106.
9. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2008; 2: 313-319.
10. Jones E, McGonagle D. Human bone marrow mesenchymal stem cells in vivo. Rheumatology (Oxford) 2008; 47: 126-131.
11. Jones EA, Kinsey SE, English A, et al. Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum 2002; 46: 3349-3360.
12. Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 2005; 7: 393-395.
13. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
14. Liu ZJ, Zhuge Y, Velazquez OC. Trafficking and differentiation of mesenchymal stem cells. J Cell Biochem 2009; 106: 984-991.
15. Augello A, Kurth TB, De Bari C. Mesenchymal stem cells: a perspective from in vitro cultures to in vivo migration and niches. Eur Cell Mater 2010; 20: 121-133.
16. Salem HK, Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 2010; 28: 585-596.
17. Bernardo ME, Cometa AM, Pagliara D, et al. Ex vivo expansion of mesenchymal stromal cells. Best Pract Res Clin Haematol 2011; 24: 73-81.
18. Nombela-Arrieta C, Ritz J, Silberstein LE. The elusive nature and function of mesenchymal stem cells. Nat Rev Mol Cell Biol 2011; 12: 126-131.
19. Si YL, Zhao YL, Hao HJ, Fu XB, Han WD. MSCs: Biological characteristics, clinical applications and their outstanding concerns. Ageing Res Rev 2011; 10: 93-103.
20. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007; 25: 2739-2749.
21. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147.
22. Delorme B, Ringe J, Gallay N, et al. Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells. Blood 2008; 111: 2631-2635.
23. da Silva ML, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 2008; 26: 2287-2299.
24. Kastrinaki MC, Andreakou I, Charbord P, Papadaki HA. Isolation of human bone marrow mesenchymal stem cells using different membrane markers: comparison of colony/cloning efficiency, differentiation potential, and molecular profile. Tissue Eng Part C Methods 2008; 14: 333-339.
25. Deschaseaux F, Pontikoglou C, Sensebe L. Bone regeneration: the stem/progenitor cells point of view. J Cell Mol Med 2010; 14: 103-115.
26. Pontikoglou C, Deschaseaux F, Sensebe L, Papadaki HA. Bone Marrow Mesenchymal Stem Cells: Biological Properties and Their Role in Hematopoiesis and Hematopoietic Stem Cell Transplantation. Stem Cell Rev 2011.
27. Chan JL, Tang KC, Patel AP, et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 2006; 107: 4817-4824.
28. Stagg J. Immune regulation by mesenchymal stem cells: two sides to the coin. Tissue Antigens 2007; 69: 1-9.
29. Pontikoglou C, Delorme B, Charbord P. Human bone marrow native mesenchymal stem cells. Regen Med 2008; 3: 731-741.
30. Simmons PJ, Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 1991; 78: 55-62.
31. Gronthos S, McCarty R, Mrozik K, et al. Heat shock protein-90 beta is expressed at the surface of multipotential mesenchymal precursor cells: generation of a novel monoclonal antibody, STRO-4, with specificity for mesenchymal precursor cells from human and ovine tissues. Stem Cells Dev 2009; 18: 1253-1262.
32. Buhring HJ, Battula VL, Treml S, Schewe B, Kanz L, Vogel W. Novel markers for the prospective isolation of human MSC. Ann N Y Acad Sci 2007; 1106: 262-271.
33. Battula VL, Treml S, Bareiss PM, et al. Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haema-tologica 2009; 94: 173-184.
34. Quirici N, Soligo D, Bossolasco P, Servida F, Lumini C, Deliliers GL. Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Exp Hematol 2002; 30: 783-791.
35. Kuci S, Kuci Z, Kreyenberg H, et al. CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haema-tologica 2010; 95: 651-659.
36. Takashima Y, Era T, Nakao K, et al. Neuroepithelial cells supply an initial transient wave of MSC differentiation. Cell 2007; 129: 1377-1388.
37. Morikawa S, Mabuchi Y, Niibe K, et al. Development of mesen-chymal stem cells partially originate from the neural crest. Bio-chem Biophys Res Commun 2009; 379: 1114-1119.
38. Martinez C, Hofmann TJ, Marino R, Dominici M, Horwitz EM. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood 2007; 109: 4245-4248.
39. Gang EJ, Bosnakovski D, Figueiredo CA, Visser JW, Perlingeiro RC. SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood 2007; 109: 1743-1751.
40. Deschaseaux F, Charbord P. Human marrow stromal precursors are alpha 1 integrin subunit-positive. J Cell Physiol 2000; 184: 319-325.
41. Song L, Webb NE, Song Y, Tuan RS. Identification and functional analysis of candidate genes regulating mesenchymal stem cell self-renewal and multipotency. Stem Cells 2006; 24: 1707-1718.
42. Kubo H, Shimizu M, Taya Y, et al. Identification of mesenchymal stem cell (MSC)-transcription factors by microarray and knockdown analyses, and signature molecule-marked MSC in bone marrow by immunohistochemistry. Genes Cells 2009; 14: 407-424.
43. Kaltz N, Ringe J, Holzwarth C, et al. Novel markers of mesenchy-mal stem cells defined by genome-wide gene expression analysis of stromal cells from different sources. Exp Cell Res 2010; 316: 2609-2617.
44. Sacchetti B, Funari A, Michienzi S, et al. Self-renewing osteopro-genitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007; 131: 324-336.
45. Crisan M, Yap S, Casteilla L, et al. A perivascular origin for mes-enchymal stem cells in multiple human organs. Cell Stem Cell 2008; 3: 301-313.
46. da Silva ML, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006; 119: 2204-2213.
47. Gronthos S, Mankani M, Brahim J, Robey PG, Shi S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci U S A 2000; 97: 13625-13630.
48. Williams JT, Southerland SS, Souza J, Calcutt AF, Cartledge RG. Cells isolated from adult human skeletal muscle capable of differentiating into multiple mesodermal phenotypes. Am Surg 1999; 65: 22-26.
49. De Bari C., Dell'Accio F, Tylzanowski P, Luyten FP. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 2001; 44: 1928-1942.
50. Kuznetsov SA, Mankani MH, Gronthos S, Satomura K, Bianco P, Robey PG. Circulating skeletal stem cells. J Cell Biol 2001; 153: 1133-1140.
51. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001; 7: 211-228.
52. In't Anker PS, Scherjon SA, Kleijburg-van der KC, et al. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood 2003; 102: 1548-1549.
53. Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000; 109: 235-242.
54. Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk NM. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001; 98: 2396-2402.
55. Fan CG, Tang FW, Zhang QJ, et al. Characterization and neural differentiation of fetal lung mesenchymal stem cells. Cell Transplant 2005; 14: 311-321.
56. Gimble JM, Guilak F, Nuttall ME, Sathishkumar S, Vidal M, Bun-nell BA. In vitro Differentiation Potential of Mesenchymal Stem Cells. Transfus Med Hemother 2008; 35: 228-238.
57. Charbord P. Bone marrow mesenchymal stem cells: historical overview and concepts. Hum Gene Ther 2010; 21: 1045-1056.
58. Remy-Martin JP, Marandin A, Challier B, et al. Vascular smooth muscle differentiation of murine stroma: a sequential model. Exp Hematol 1999; 27: 1782-1795.
59. Delorme B, Ringe J, Pontikoglou C, et al. Specific lineage-priming of bone marrow mesenchymal stem cells provides the molecular framework for their plasticity. Stem Cells 2009; 27: 1142-1151.
60. Wakitani S, Saito T, Caplan AI. Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve 1995; 18: 1417-1426.
61. Chagraoui J, Lepage-Noll A, Anjo A, Uzan G, Charbord P. Fetal liver stroma consists of cells in epithelial-to-mesenchymal transition. Blood 2003; 101: 2973-2982.
62. Oswald J, Boxberger S, Jorgensen B, et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004; 22: 377-384.
63. Bossolasco P, Cova L, Calzarossa C, et al. Neuro-glial differentiation of human bone marrow stem cells in vitro. Exp Neurol 2005; 193: 312-325.
64. Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999; 103: 697-705.
65. Gojo S, Gojo N, Takeda Y, et al. In vivo cardiovasculogenesis by direct injection of isolated adult mesenchymal stem cells. Exp Cell Res 2003; 288: 51-59.
66. Barbash IM, Chouraqui P, Baron J, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 2003; 108: 863-868.
67. Psaltis PJ, Zannettino AC, Worthley SG, Gronthos S. Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells 2008; 26: 2201-2210.
68. Petrie Aronin CE, Tuan RS. Therapeutic potential of the immuno-modulatory activities of adult mesenchymal stem cells. Birth Defects Res C Embryo Today 2010; 90: 67-74.
69. Ankrum J, Karp JM. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med 2010; 16: 203-209.
70. Zuk PA. The adipose-derived stem cell: looking back and looking ahead. Mol Biol Cell 2010; 21: 1783-1787.
71. Witkowska-Zimny M, Walenko K. Stem cells from adipose tissue. Cell Mol Biol Lett 2011; 16: 236-257.
72. Lindroos B, Suuronen R, Miettinen S. The potential of adipose stem cells in regenerative medicine. Stem Cell Rev 2011; 7: 269-291.
73. Locke M, Feisst V, Dunbar PR. Concise Review: Human Adipose-Derived Stem Cells (ASC): Separating Promise from Clinical Need. Stem Cells 2011; 29: 404-411.
74. Gesta S, Tseng YH, Kahn CR. Developmental origin of fat: tracking obesity to its source. Cell 2007; 131: 242-256.
75. Tchkonia T, Morbeck DE, Von Zglinicki T., et al. Fat tissue, aging, and cellular senescence. Aging Cell 2010; 9: 667-684.
76. Berryman DE, List EO, Sackmann-Sala L, Lubbers E, Munn R, Kopchick JJ. Growth hormone and adipose tissue: Beyond the adi-pocyte. Growth Horm IGF Res 2011; e-pub.
77. Klaus S. Adipose tissue as a regulator of energy balance. Curr Drug Targets 2004; 5: 241-250.
78. Guo W, Pirtskhalava T, Tchkonia T, et al. Aging results in paradoxical susceptibility of fat cell progenitors to lipotoxicity. Am J Physiol Endocrinol Metab 2007; 292: E1041-E1051.
79. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556.
80. Katz AJ, Llull R, Hedrick MH, Futrell JW. Emerging approaches to the tissue engineering of fat. Clin Plast Surg 1999; 26: 587-603.
81. Zhu Y, Liu T, Song K, Fan X, Ma X, Cui Z. Adipose-derived stem cell: a better stem cell than BMSC. Cell Biochem Funct 2008; 26: 664-675.
82. Mitchell JB, McIntosh K, Zvonic S, et al. Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cell-associated markers. Stem Cells 2006; 24: 376-385.
83. Williams SK, McKenney S, Jarrell BE. Collagenase lot selection and purification for adipose tissue digestion. Cell Transplant 1995; 4: 281-289.
84. Gimble J, Guilak F. Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. Cytotherapy 2003; 5: 362-369.
85. Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002; 13: 4279-4295.
86. Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. Circ Res 2007; 100: 1249-1260.
87. Planat-Benard V, Silvestre JS, Cousin B, et al. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation 2004; 109: 656-663.
88. Rada T, Reis RL, Gomes ME. Adipose tissue-derived stem cells and their application in bone and cartilage tissue engineering. Tissue Eng Part B Rev 2009; 15: 113-125.
89. Safford KM, Hicok KC, Safford SD, et al. Neurogenic differentiation of murine and human adipose-derived stromal cells. Biochem Biophys Res Commun 2002; 294: 371-379.
90. Seo MJ, Suh SY, Bae YC, Jung JS. Differentiation of human adipose stromal cells into hepatic lineage in vitro and in vivo. Biochem Biophys Res Commun 2005; 328: 258-264.
91. Timper K, Seboek D, Eberhardt M, et al. Human adipose tissue-derived mesenchymal stem cells differentiate into insulin, soma-tostatin, and glucagon expressing cells. Biochem Biophys Res Commun 2006; 341: 1135-1140.
92. Fraser JK, Wulur I, Alfonso Z, Hedrick MH. Fat tissue: an underappreciated source of stem cells for biotechnology. Trends Bio-technol 2006; 24: 150-154.
93. Daher SR, Johnstone BH, Phinney DG, March KL. Adipose stro-mal/stem cells: basic and translational advances: the IFATS collection. Stem Cells 2008; 26: 2664-2665.
94. Schaffler A, Buchler C. Concise review: adipose tissue-derived stromal cells--basic and clinical implications for novel cell-based therapies. Stem Cells 2007; 25: 818-827.
95. Katz AJ, Tholpady A, Tholpady SS, Shang H, Ogle RC. Cell surface and transcriptional characterization of human adipose-derived adherent stromal (hADAS) cells. Stem Cells 2005; 23: 412-423.
96. Nakagami H, Morishita R, Maeda K, Kikuchi Y, Ogihara T, Kaneda Y. Adipose tissue-derived stromal cells as a novel option for regenerative cell therapy. J Atheroscler Thromb 2006; 13: 77-81.
97. Gronthos S, Franklin DM, Leddy HA, Robey PG, Storms RW, Gimble JM. Surface protein characterization of human adipose tissue-derived stromal cells. J Cell Physiol 2001; 189: 54-63.
98. Dawn B, Bolli R. Adult bone marrow-derived cells: regenerative potential, plasticity, and tissue commitment. Basic Res Cardiol 2005; 100: 494-503.
99. De Ugarte DA, Alfonso Z, Zuk PA, et al. Differential expression of stem cell mobilization-associated molecules on multi-lineage cells from adipose tissue and bone marrow. Immunol Lett 2003; 89: 267-270.
100. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006; 24: 1294-1301.
101. Romanov YA, Darevskaya AN, Merzlikina NV, Buravkova LB. Mesenchymal stem cells from human bone marrow and adipose tissue: isolation, characterization, and differentiation potentialities. Bull Exp Biol Med 2005; 140: 138-143.
102. Puissant B, Barreau C, Bourin P, et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol 2005; 129: 118-129.
103. Wagner W, Wein F, Seckinger A, et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 2005; 33: 1402-1416.
104. Brivanlou AH, Gage FH, Jaenisch R, Jessell T, Melton D, Rossant J. Stem cells. Setting standards for human embryonic stem cells. Science 2003; 300: 913-916.
105. McIntosh K, Zvonic S, Garrett S, et al. The immunogenicity of human adipose-derived cells: temporal changes in vitro. Stem Cells 2006; 24: 1246-1253.
106. Strem BM, Hicok KC, Zhu M, et al. Multipotential differentiation of adipose tissue-derived stem cells. Keio J Med 2005; 54: 132-141.
107. Garcia-Castro J, Trigueros C, Madrenas J, Perez-Simon JA, Rodriguez R, Menendez P. Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. J Cell Mol Med 2008; 12: 2552-2565.
108. Tapp H, Hanley EN, Patt JC, Gruber HE. Adipose-derived stem cells: characterization and current application in orthopaedic tissue repair. Exp Biol Med (Maywood) 2008.
109. Jiang T, Liu W, Lv X, et al. Potent in vitro chondrogenesis of CD105 enriched human adipose-derived stem cells. Biomaterials 2010; 31: 3564-3571.
110. Quirici N, Scavullo C, de Girolamo L, et al. Anti-L-NGFR and -CD34 monoclonal antibodies identify multipotent mesenchymal stem cells in human adipose tissue. Stem Cells Dev 2010; 19: 915-925.
111. Zimmerlin L, Donnenberg VS, Pfeifer ME, et al. Stromal vascular progenitors in adult human adipose tissue. Cytometry A 2010; 77: 22-30.
112. Smas CM, Sul HS. Pref-1, a protein containing EGF-like repeats, inhibits adipocyte differentiation. Cell 1993; 73: 725-734.
113. Zannettino AC, Paton S, Arthur A, et al. Multipotential human adipose-derived stromal stem cells exhibit a perivascular phenotype in vitro and in vivo. J Cell Physiol 2008; 214: 413-421.
114. Maumus M, Peyrafitte JA, D'Angelo R, et al. Native human adipose stromal cells: localization, morphology and phenotype. Int J Obes (Lond) 2011; e-pub.
115. Parker AM, Shang H, Khurgel M, Katz AJ. Low serum and serum-free culture of multipotential human adipose stem cells. Cytother-apy 2007; 9: 637-646.
116. Lindroos B, Boucher S, Chase L, et al. Serum-free, xeno-free culture media maintain the proliferation rate and multipotentiality of adipose stem cells in vitro. Cytotherapy 2009; 11: 958-972.
117. Lindroos B, Aho KL, Kuokkanen H, et al. Differential gene expression in adipose stem cells cultured in allogeneic human serum versus fetal bovine serum. Tissue Eng Part A 2010; 16: 2281-2294.
118. Peroni D, Scambi I, Pasini A, et al. Stem molecular signature of adipose-derived stromal cells. Exp Cell Res 2008; 314: 603-615.
119. Egusa H, Iida K, Kobayashi M, et al. Downregulation of extracellular matrix-related gene clusters during osteogenic differentiation of human bone marrow- and adipose tissue-derived stromal cells. Tissue Eng 2007; 13: 2589-2600.
120. Stolzing A, Jones E, McGonagle D, Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev 2008; 129: 163-173.
121. Rodda DJ, Chew JL, Lim LH, et al. Transcriptional regulation of nanog by OCT4 and SOX2. J Biol Chem 2005; 280: 24731-24737.
122. Liedtke S, Enczmann J, Waclawczyk S, Wernet P, Kogler G. Oct4 and its pseudogenes confuse stem cell research. Cell Stem Cell 2007; 1: 364-366.
123. Prunet-Marcassus B, Cousin B, Caton D, Andre M, Penicaud L, Casteilla L. From heterogeneity to plasticity in adipose tissues: site-specific differences. Exp Cell Res 2006; 312: 727-736.
124. Fraser JK, Wulur I, Alfonso Z, Zhu M, Wheeler ES. Differences in stem and progenitor cell yield in different subcutaneous adipose tissue depots. Cytotherapy 2007; 9: 459-467.
125. Kilroy GE, Foster SJ, Wu X, et al. Cytokine profile of human adipose-derived stem cells: expression of angiogenic, hematopoietic, and pro-inflammatory factors. J Cell Physiol 2007; 212: 702-709.
126. Salgado AJ, Reis RL, Sousa NJ, Gimble JM. Adipose tissue derived stem cells secretome: soluble factors and their roles in regenerative medicine. Curr Stem Cell Res Ther 2010; 5: 103-110.
127. Hennig T, Lorenz H, Thiel A, et al. Reduced chondrogenic potential of adipose tissue derived stromal cells correlates with an altered TGFbeta receptor and BMP profile and is overcome by BMP-6. J Cell Physiol 2007; 211: 682-691.
128. Awad HA, Halvorsen YD, Gimble JM, Guilak F. Effects of transforming growth factor beta1 and dexamethasone on the growth and chondrogenic differentiation of adipose-derived stromal cells. Tissue Eng 2003; 9: 1301-1312.
129. Mahmoudifar N, Doran PM. Chondrogenic differentiation of human adipose-derived stem cells in polyglycolic acid mesh scaffolds under dynamic culture conditions. Biomaterials 2010; 31: 3858-3867.
130. Jin X, Sun Y, Zhang K, et al. Ectopic neocartilage formation from predifferentiated human adipose derived stem cells induced by adenoviral-mediated transfer of hTGF beta2. Biomaterials 2007; 28: 2994-3003.
131. Zhao Y, Lin H, Zhang J, et al. Crosslinked three-dimensional dem-ineralized bone matrix for the adipose-derived stromal cell proliferation and differentiation. Tissue Eng Part A 2009; 15: 13-21.
132. Hong L, Colpan A, Peptan IA, Daw J, George A, Evans CA. 17-Beta estradiol enhances osteogenic and adipogenic differentiation of human adipose-derived stromal cells. Tissue Eng 2007; 13: 1197-1203.
133. Lee JH, Rhie JW, Oh DY, Ahn ST. Osteogenic differentiation of human adipose tissue-derived stromal cells (hASCs) in a porous three-dimensional scaffold. Biochem Biophys Res Commun 2008; 370: 456-460.
134. Jeon O, Rhie JW, Kwon IK, Kim JH, Kim BS, Lee SH. In vivo bone formation following transplantation of human adipose-derived stromal cells that are not differentiated osteogenically. Tissue Eng Part A 2008; 14: 1285-1294.
135. Lin Y, Wang T, Wu L, et al. Ectopic and in situ bone formation of adipose tissue-derived stromal cells in biphasic calcium phosphate nanocomposite. J Biomed Mater Res A 2007; 81: 900-910.
136. Li X, Yao J, Wu L, et al. Osteogenic induction of adipose-derived stromal cells: not a requirement for bone formation in vivo. Artif Organs 2010; 34: 46-54.
137. Gastaldi G, Asti A, Scaffino MF, et al. Human adipose-derived stem cells (hASCs) proliferate and differentiate in osteoblast-like cells on trabecular titanium scaffolds. J Biomed Mater Res A 2010; 94: 790-799.
138. Mauney JR, Nguyen T, Gillen K, Kirker-Head C, Gimble JM, Kaplan DL. Engineering adipose-like tissue in vitro and in vivo utilizing human bone marrow and adipose-derived mesenchymal stem cells with silk fibroin 3D scaffolds. Biomaterials 2007; 28: 5280-5290.
139. Brayfield C, Marra K, Rubin JP. Adipose stem cells for soft tissue regeneration. Handchir Mikrochir Plast Chir 2010; 42: 124-128.
140. Brzoska M, Geiger H, Gauer S, Baer P. Epithelial differentiation of human adipose tissue-derived adult stem cells. Biochem Biophys Res Commun 2005; 330: 142-150.
141. Rodriguez-Serrano F, Alvarez P, Caba O, et al. Promotion of human adipose-derived stem cell proliferation mediated by exogenous nucleosides. Cell Biol Int 2010; 34: 917-924.
142. Froehlich H, Gulati R, Boilson B, et al. Carotid repair using autologous adipose-derived endothelial cells. Stroke 2009; 40: 1886-1891.
143. Madonna R, De Caterina CR. In vitro neovasculogenic potential of resident adipose tissue precursors. Am J Physiol Cell Physiol 2008; 295: C1271-C1280.
144. Heydarkhan-Hagvall S, Schenke-Layland K, Yang JQ, et al. Human adipose stem cells: a potential cell source for cardiovascular tissue engineering. Cells Tissues Organs 2008; 187: 263-274.
145. Verseijden F, Posthumus-van Sluijs SJ, Pavljasevic P, Hofer SO, van Osch GJ, Farrell E. Adult human bone marrow- and adipose tissue-derived stromal cells support the formation of prevascular-like structures from endothelial cells in vitro. Tissue Eng Part A 2010; 16: 101-114.
146. Scherberich A, Galli R, Jaquiery C, Farhadi J, Martin I. Three-dimensional perfusion culture of human adipose tissue-derived en-dothelial and osteoblastic progenitors generates osteogenic constructs with intrinsic vascularization capacity. Stem Cells 2007; 25: 1823-1829.
147. Muller AM, Mehrkens A, Schafer DJ, et al. Towards an intraopera-tive engineering of osteogenic and vasculogenic grafts from the stromal vascular fraction of human adipose tissue. Eur Cell Mater 2010; 19: 127-135.
148. Nakada A, Fukuda S, Ichihara S, et al. Regeneration of central nervous tissue using a collagen scaffold and adipose-derived stro-mal cells. Cells Tissues Organs 2009; 190: 326-335.
149. Erba P, Terenghi G, Kingham PJ. Neural differentiation and therapeutic potential of adipose tissue derived stem cells. Curr Stem Cell Res Ther 2010; 5: 153-160.
150. Okura H, Komoda H, Fumimoto Y, et al. Transdifferentiation of human adipose tissue-derived stromal cells into insulin-producing clusters. J Artif Organs 2009; 12: 123-130.
151. Kajiyama H, Hamazaki TS, Tokuhara M, et al. Pdx1-transfected adipose tissue-derived stem cells differentiate into insulin-producing cells in vivo and reduce hyperglycemia in diabetic mice. Int J Dev Biol 2010; 54: 699-705.
152. Long JL, Zuk P, Berke GS, Chhetri DK. Epithelial differentiation of adipose-derived stem cells for laryngeal tissue engineering. Laryngoscope 2010; 120: 125-131.
153. Banas A, Teratani T, Yamamoto Y, et al. Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. Hepa-tology 2007; 46: 219-228.
154. Aurich H, Sgodda M, Kaltwasser P, et al. Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. Gut 2009; 58: 570-581.
155. Jeong JH, Lee JH, Jin ES, Min JK, Jeon SR, Choi KH. Regeneration of intervertebral discs in a rat disc degeneration model by implanted adipose-tissue-derived stromal cells. Acta Neurochir (Wien) 2010; 152: 1771-1777.
156. da Silva M.L., Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 2009; 20: 419-427.
157. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8: 726-736.
158. Ghannam S, Bouffi C, Djouad F, Jorgensen C, Noel D. Immuno-suppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther 2010; 1: 2.
159. Sensebe L, Krampera M, Schrezenmeier H, Bourin P, Giordano R. Mesenchymal stem cells for clinical application. Vox Sang 2010; 98: 93-107.
160. Shi Y, Hu G, Su J, et al. Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res 2010; 20: 510-518.
161. Yagi H, Soto-Gutierrez A, Parekkadan B, et al. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant 2010; 19: 667-679.
162. Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol 2011; 6: 457-478.
163. Solana R, Mariani E. NK and NK/T cells in human senescence. Vaccine 2000; 18: 1613-1620.
164. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytoly-sis. Annu Rev Immunol 2001; 19: 197-223.
165. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papa-michail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74-85.
166. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006; 107: 1484-1490.
167. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of in-doleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008; 111: 1327-1333.
168. Poggi A, Prevosto C, Massaro AM, et al. Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J Immunol 2005; 175: 6352-6360.
169. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822.
170. Gotherstrom C, Lundqvist A, Duprez IR, Childs R, Berg L, Le Blanc K. Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways. Cytotherapy 2011; 13: 269-278.
171. Raffaghello L, Bianchi G, Bertolotto M, et al. Human mesenchy-mal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 2008; 26: 151-162.
172. Fadeel B, Ahlin A, Henter JI, Orrenius S, Hampton MB. Involvement of caspases in neutrophil apoptosis: regulation by reactive oxygen species. Blood 1998; 92: 4808-4818.
173. Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol 2009; 37: 1445-1453.
174. Jiang XX, Zhang Y, Liu B, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120-4126.
175. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 2006; 177: 2080-2087.
176. Di Nicola M., Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843.
177. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42-48.
178. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stro-mal cells: implications in transplantation. Transplantation 2003; 75: 389-397.
179. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloan-tigens by different mechanisms. Exp Cell Res 2005; 305: 33-41.
180. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105: 2821-2827.
181. Benvenuto F, Ferrari S, Gerdoni E, et al. Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells 2007; 25: 1753-1760.
182. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76: 1208-1213.
183. Maccario R, Podesta M, Moretta A, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005; 90: 516-525.
184. Di Ianni M, Del Papa B, De Ioanni M, et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 2008; 36: 309-318.
185. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 2007; 92: 881-888.
186. Selmani Z, Naji A, Zidi I, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26: 212-222.
187. Augello A, Tasso R, Negrini SM, et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005; 35: 1482-1490.
188. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367-372.
189. Rasmusson I, Le Blanc K., Sundberg B, Ringden O. Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol 2007; 65: 336-343.
190. Traggiai E, Volpi S, Schena F, et al. Bone marrow-derived mesen-chymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 2008; 26: 562-569.
191. Krampera M, Cosmi L, Angeli R, et al. Role for interferon-g in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24: 386-398.
192. Sato K, Ozaki K, Oh I, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109: 228-234.
193. Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-150.
194. Djouad F, Charbonnier LM, Bouffi C, et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an inter-leukin-6-dependent mechanism. Stem Cells 2007; 25: 2025-2032.
195. Selmani Z, Naji A, Gaiffe E, et al. HLA-G is a crucial immunosup-pressive molecule secreted by adult human mesenchymal stem cells. Transplantation 2009; 87: S62-S66.
196. Le Blanc K., Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57: 11-20.
197. Chan WK, Lau AS, Li JC, Law HK, Lau YL, Chan GC. MHC expression kinetics and immunogenicity of mesenchymal stromal cells after short-term IFN-gamma challenge. Exp Hematol 2008; 36: 1545-1555.
198. Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007; 149: 353-363.
199. Stagg J, Pommey S, Eliopoulos N, Galipeau J. Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood 2006; 107: 2570-2577.
200. Harvath L. Food and Drug Administration's proposed approach to regulation of hematopoietic stem/progenitor cell products for therapeutic use. Transfus Med Rev 2000; 14: 104-111.
201. DIRECTIVE 2001/83/EC of the European Parliament and of the Council on the Community Code Relating to Medicinal Products for Human Use. The European Parliament and of the Council of the Community. 83 [2001] Available from URL: http://www.emea.europa.eu/pdfs/human/pmf/2001-83-EC.pdf.
202. Guideline on Human Cell-Based Medicinal Products. EMEA, Committee for Human Medicinal Products. [2008] Available from URL: http://www.emea.europa.eu/pdfs/human/cpwp/41086906enfin.pdf.
203. Rhemann W, Morgan G. The regulation of advanced therapies: perspectives from the EU Regulatory Feature. [2009] Available fromURL: http://www.taylorwessing.com/uploads/tx_siruplawyermanagement/The_Regulation_of_Advanced_Therapies.pdf
204. Halme DG, Kessler DA. FDA regulation of stem-cell-based therapies. N Engl J Med 2006; 355: 1730-1735.
205. Burger SR. Design and operation of a current good manufacturing practices cell-engineering laboratory. Cytotherapy 2000; 2: 111-122.
206. Regulation (EC) no 1394/2007 of the European Parliament and of the Council. Official Journal of the European Union. [2007] Available from URL: http://eur-lex.europa.eu/LexUriServ/LexUriServ.
207. Bieback K, Kinzebach S, Karagianni M. Translating research into clinical scale manufacturing of mesenchymal stromal cells. Stem Cells Int 2011; 2010: 193519.
208. Bourin P, Sensebe L, Planat-Benard V, Roncalli J, Bura-Riviere A, Casteilla L. Culture and Use of Mesenchymal Stromal Cells in Phase I and II Clinical Trials. Stem Cells Int 2010; 2010: 503593.
209. Liras A. Future research and therapeutic applications of human stem cells: general, regulatory, and bioethical aspects. J Transl Med 2010; 8: 131.
210. Sensebe L, Bourin P, Tarte K. Good manufacturing practices production of mesenchymal stem/stromal cells. Hum Gene Ther 2011; 22: 19-26.
211. Gimble JM, Bunnell BA, Chiu ES, Guilak F. Concise Review: Adipose-Derived Stromal Vascular Fraction Cells and Stem Cells: Let's Not Get Lost in Translation. Stem Cells 2011; 29: 749-754.
212. Bieback K, Hecker A, Kocaomer A, et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 2009; 27: 2331-2341.
213. Herrera B, Inman GJ. A rapid and sensitive bioassay for the simultaneous measurement of multiple bone morphogenetic proteins. Identification and quantification of BMP4, BMP6 and BMP9 in bovine and human serum. BMC Cell Biol 2009; 10: 20.
214. Mackensen A, Drager R, Schlesier M, Mertelsmann R, Lindemann A. Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol Immunother 2000; 49: 152-156.
215. Selvaggi TA, Walker RE, Fleisher TA. Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. Blood 1997; 89: 776-779.
216. Heiskanen A, Satomaa T, Tiitinen S, et al. N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. Stem Cells 2007; 25: 197-202.
217. Stute N, Holtz K, Bubenheim M, Lange C, Blake F, Zander AR. Autologous serum for isolation and expansion of human mesen-chymal stem cells for clinical use. Exp Hematol 2004; 32: 1212-1225.
218. Koller MR, Maher RJ, Manchel I, Oxender M, Smith AK. Alternatives to animal sera for human bone marrow cell expansion: human serum and serum-free media. J Hematother 1998; 7: 413-423.
219. Nimura A, Muneta T, Koga H, et al. Increased proliferation of human synovial mesenchymal stem cells with autologous human serum: comparisons with bone marrow mesenchymal stem cells and with fetal bovine serum. Arthritis Rheum 2008; 58: 501-510.
220. Yamamoto N, Isobe M, Negishi A, et al. Effects of autologous serum on osteoblastic differentiation in human bone marrow cells. J Med Dent Sci 2003; 50: 63-69.
221. Yamaguchi M, Hirayama F, Wakamoto S, et al. Bone marrow stromal cells prepared using AB serum and bFGF for hema-topoietic stem cells expansion. Transfusion 2002; 42: 921-927.
222. Oreffo RO, Triffitt JT. Future potentials for using osteogenic stem cells and biomaterials in orthopedics. Bone 1999; 25: 5S-9S.
223. Johansson L, Klinth J, Holmqvist O, Ohlson S. Platelet lysate: a replacement for fetal bovine serum in animal cell culture? Cytotechnology 2003; 42: 67-74.
224. Salvade A, Della MP, Gaddi D, et al. Characterization of platelet lysate cultured mesenchymal stromal cells and their potential use in tissue-engineered osteogenic devices for the treatment of bone defects. Tissue Eng Part C Methods 2010; 16: 201-214.
225. Lepperdinger G, Brunauer R, Jamnig A, Laschober G, Kassem M. Controversial issue: is it safe to employ mesenchymal stem cells in cell-based therapies? Exp Gerontol 2008; 43: 1018-1023.
226. Meuleman N, Tondreau T, Delforge A, et al. Human marrow mes-enchymal stem cell culture: serum-free medium allows better expansion than classical alpha-MEM medium. Eur J Haematol 2006; 76: 309-316.
227. Rajala K, Lindroos B, Hussein SM, et al. A defined and xeno-free culture method enabling the establishment of clinical-grade human embryonic, induced pluripotent and adipose stem cells. PLoS One 2010; 5: e10246.
228. Boquest AC, Shahdadfar A, Fronsdal K, et al. Isolation and transcription profiling of purified uncultured human stromal stem cells: alteration of gene expression after in vitro cell culture. Mol Biol Cell 2005; 16: 1131-1141.
229. Izadpanah R, Kaushal D, Kriedt C, et al. Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res 2008; 68: 4229-4238.
230. Sepe A, Tchkonia T, Thomou T, Zamboni M, Kirkland JL. Aging and regional differences in fat cell progenitors - a mini-review. Gerontology 2011; 57: 66-75.
231. Majka SM, Fox KE, Psilas JC, et al. De novo generation of white adipocytes from the myeloid lineage via mesenchymal intermediates is age, adipose depot, and gender specific. Proc Natl Acad Sci U S A 2010; 107: 14781-14786.
232. Schipper BM, Marra KG, Zhang W, Donnenberg AD, Rubin JP. Regional anatomic and age effects on cell function of human adipose-derived stem cells. Ann Plast Surg 2008; 60: 538-544.
233. Zhu M, Kohan E, Bradley J, Hedrick M, Benhaim P, Zuk P. The effect of age on osteogenic, adipogenic and proliferative potential of female adipose-derived stem cells. J Tissue Eng Regen Med 2009; 3: 290-301.
234. Madonna R, Renna FV, Cellini C, et al. Age-dependent impairment of number and angiogenic potential of adipose tissue-derived progenitor cells. Eur J Clin Invest 2011; 41: 126-133.
235. van Harmelen V, Skurk T, Rohrig K, et al. Effect of BMI and age on adipose tissue cellularity and differentiation capacity in women. Int J Obes Relat Metab Disord 2003; 27: 889-895.
236. Aksu AE, Rubin JP, Dudas JR, Marra KG. Role of gender and anatomical region on induction of osteogenic differentiation of human adipose-derived stem cells. Ann Plast Surg 2008; 60: 306-322.
237. Bellantuono I, Aldahmash A, Kassem M. Aging of marrow stromal (skeletal) stem cells and their contribution to age-related bone loss. Biochim Biophys Acta 2009; 1792: 364-370.
238. Ertl R.P., Chen J, Astle CM, Duffy TM, Harrison DE. Effects of dietary restriction on hematopoietic stem-cell aging are genetically regulated. Blood 2008; 111: 1709-1716.
239. Egrise D, Martin D, Vienne A, Neve P, Schoutens A. The number of fibroblastic colonies formed from bone marrow is decreased and the in vitro proliferation rate of trabecular bone cells increased in aged rats. Bone 1992; 13: 355-361.
240. Quarto R, Thomas D, Liang CT. Bone progenitor cell deficits and the age-associated decline in bone repair capacity. Calcif Tissue Int 1995; 56: 123-129.
241. Oreffo RO, Bord S, Triffitt JT. Skeletal progenitor cells and ageing human populations. Clin Sci (Lond) 1998; 94: 549-555.
242. Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ, Bellan-tuono I. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells 2004; 22: 675-682.
243. Stenderup K, Justesen J, Eriksen EF, Rattan SI, Kassem M. Number and proliferative capacity of osteogenic stem cells are maintained during aging and in patients with osteoporosis. J Bone Miner Res 2001; 16: 1120-1129.
244. Bellantuono I, Keith WN. Stem cell ageing: does it happen and can we intervene? Expert Rev Mol Med 2007; 9: 1-20.
245. Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 2003; 33: 919-926.
246. Justesen J, Stenderup K, Eriksen EF, Kassem M. Maintenance of osteoblastic and adipocytic differentiation potential with age and osteoporosis in human marrow stromal cell cultures. Calcif Tissue Int 2002; 71: 36-44.
247. Muraglia A, Cancedda R, Quarto R. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci 2000; 113 (Pt 7): 1161-1166.
248. Zhou YF, Bosch-Marce M, Okuyama H, et al. Spontaneous transformation of cultured mouse bone marrow-derived stromal cells. Cancer Res 2006; 66: 10849-10854.
249. Miura M, Miura Y, Padilla-Nash HM, et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 2006; 24: 1095-1103.
250. Aguilar S, Nye E, Chan J, et al. Murine but not human mesenchy-mal stem cells generate osteosarcoma-like lesions in the lung. Stem Cells 2007; 25: 1586-1594.
251. Bernardo ME, Zaffaroni N, Novara F, et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 2007; 67: 9142-9149.
252. Kim J, Kang JW, Park JH, et al. Biological characterization of long-term cultured human mesenchymal stem cells. Arch Pharm Res 2009; 32: 117-126.
253. Meza-Zepeda LA, Noer A, Dahl JA, Micci F, Myklebost O, Collas P. High-resolution analysis of genetic stability of human adipose tissue stem cells cultured to senescence. J Cell Mol Med 2008; 12: 553-563.
254. Choumerianou DM, Dimitriou H, Perdikogianni C, Martimianaki G, Riminucci M, Kalmanti M. Study of oncogenic transformation in ex vivo expanded mesenchymal cells, from paediatric bone marrow. Cell Prolif 2008; 41: 909-922.
255. Wang Y, Huso DL, Harrington J, et al. Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. Cytotherapy 2005; 7: 509-519.
256. Serakinci N, Guldberg P, Burns JS, et al. Adult human mesenchy-mal stem cell as a target for neoplastic transformation. Oncogene 2004; 23: 5095-5098.
257. Burns JS, Abdallah BM, Guldberg P, Rygaard J, Schroder HD, Kassem M. Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells. Cancer Res 2005; 65: 3126-3135.
258. Rubio D, Garcia-Castro J, Martin MC, et al. Spontaneous human adult stem cell transformation. Cancer Res 2005; 65: 3035-3039.
259. Rubio D, Garcia S, De la Cueva T, et al. Human mesenchymal stem cell transformation is associated with a mesenchymal-epithelial transition. Exp Cell Res 2008; 314: 691-698.
260. Rosland GV, Svendsen A, Torsvik A, et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res 2009; 69: 5331-5339.
261. de la Fuente R, Bernad A, Garcia-Castro J, Martin MC, Cigudosa JC. Retraction: Spontaneous human adult stem cell transformation. Cancer Res 2010; 70: 6682.
262. Torsvik A, Rosland GV, Svendsen A, et al. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter. Cancer Res 2010; 70: 6393-6396.
263. Garcia S, Bernad A, Martin MC, Cigudosa JC, Garcia-Castro J, de la Fuente R. Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells. Exp Cell Res 2010; 316: 1648-1650.
264. Tarte K, Gaillard J, Lataillade JJ, et al. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 2010; 115: 1549-1553.
265. Shibata KR, Aoyama T, Shima Y, et al. Expression of the p16INK4A gene is associated closely with senescence of human mesenchymal stem cells and is potentially silenced by DNA methy-lation during in vitro expansion. Stem Cells 2007; 25: 2371-2382.
266. Ra JC, Shin IS, Kim SH, et al. Safety of Intravenous Infusion of Human Adipose Tissue-Derived Mesenchymal Stem Cells in Animals and Humans. Stem Cells Dev 2011.
267. Lazennec G, Jorgensen C. Concise review: adult multipotent stro-mal cells and cancer: risk or benefit? Stem Cells 2008; 26: 1387-1394.
268. Helmy KY, Patel SA, Silverio K, Pliner L, Rameshwar P. Stem cells and regenerative medicine: accomplishments to date and future promise. Ther Deliv 2010; 1: 693-705.
269. Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F, III. Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells 2011; 29: 11-19.
270. Zhu W, Xu W, Jiang R, et al. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol 2006; 80: 267-274.
271. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557-563.
272. Shinagawa K, Kitadai Y, Tanaka M, et al. Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer 2010; 127: 2323-2333.
273. Muehlberg FL, Song YH, Krohn A, et al. Tissue-resident stem cells promote breast cancer growth and metastasis. Carcinogenesis 2009; 30: 589-597.
274. Prantl L, Muehlberg F, Navone NM, et al. Adipose tissue-derived stem cells promote prostate tumor growth. Prostate 2010; 70: 1709-1715.
275. Yu JM, Jun ES, Bae YC, Jung JS. Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells Dev 2008; 17: 463-473.
276. Kucerova L, Matuskova M, Hlubinova K, Altanerova V, Altaner C. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol Cancer 2010; 9: 129.
277. Lin G, Yang R, Banie L, et al. Effects of transplantation of adipose tissue-derived stem cells on prostate tumor. Prostate 2010; 70: 1066-1073.
278. Maestroni GJ, Hertens E, Galli P. Factor(s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice. Cell Mol Life Sci 1999; 55: 663-667.
279. Khakoo AY, Pati S, Anderson SA, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Ka-posi's sarcoma. J Exp Med 2006; 203: 1235-1247.
280. Secchiero P, Zorzet S, Tripodo C, et al. Human bone marrow mes-enchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. PLoS One 2010; 5: e11140.
281. Zhu Y, Sun Z, Han Q, et al. Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia 2009; 23: 925-933.
282. Cousin B, Ravet E, Poglio S, et al. Adult stromal cells derived from human adipose tissue provoke pancreatic cancer cell death both in vitro and in vivo. PLoS One 2009; 4: e6278.
283. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views. Stem Cells 2007; 25: 2896-2902.
284. Deeg HJ. How I treat refractory acute GVHD. Blood 2007; 109: 4119-26.
285. Newman RE, Yoo D, LeRoux MA, Nilkovitch-Miagkova A. Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets 2009; 8: 110-123.
286. Sato K, Ozaki K, Mori M, Muroi K, Ozawa K. Mesenchymal stro-mal cells for graft-versus-host disease: basic aspects and clinical outcomes. J Clin Exp Hematop 2010; 50: 79-89.
287. Tolar J, Villeneuve P, Keating A. Mesenchymal stromal cells for graft-versus-host disease. Hum Gene Ther 2011; 22: 257-262.
288. Le Blanc K., Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mes-enchymal stem cells. Lancet 2004; 363: 1439-1441.
289. Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81: 1390-1397.
290. Le Blanc K., Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-1586.
291. Muller I, Kordowich S, Holzwarth C, et al. Application of multipo-tent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis 2008; 40: 25-32.
292. von Bonin M, Stolzel F, Goedecke A, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009; 43: 245-251.
293. Ringden O, Le Blanc K. Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages. Best Pract Res Clin Haematol 2011; 24: 65-72.
294. Kebriaei P, Isola L, Bahceci E, et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15: 804-811.
295. Zhou H, Guo M, Bian C, et al. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol Blood Marrow Transplant 2010; 16: 403-412.
296. Weng JY, Du X, Geng SX, et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 2010; 45: 1732-1740.
297. Lazarus HM, Koc ON, Devine SM, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11: 389-398.
298. Ning H, Yang F, Jiang M, et al. The correlation between cotrans-plantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008; 22: 593-599.
299. Baron F, Lechanteur C, Willems E, et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following non-myeloablative conditioning. Biol Blood Marrow Transplant 2010; 16: 838-847.
300. Yanez R, Lamana ML, Garcia-Castro J, Colmenero I, Ramirez M, Bueren JA. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 2006; 24: 2582-2591.
301. Li H, Guo Z, Jiang X, Zhu H, Li X, Mao N. Mesenchymal stem cells alter migratory property of T and dendritic cells to delay the development of murine lethal acute graft-versus-host disease. Stem Cells 2008; 26: 2531-2541.
302. Li H, Guo Z, Zhu H, et al. Transplanted mesenchymal stem cells can inhibit the three developmental stages of murine acute graft-versus-host disease. In vivo 2010; 24: 659-666.
303. Sudres M, Norol F, Trenado A, et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 2006; 176: 7761-7767.
304. Badillo AT, Peranteau WH, Heaton TE, Quinn C, Flake AW. Mur-ine bone marrow derived stromal progenitor cells fail to prevent or treat acute graft-versus-host disease. Br J Haematol 2008; 141: 224-234.
305. Fang B, Song Y, Zhao RC, Han Q, Lin Q. Using human adipose tissue-derived mesenchymal stem cells as salvage therapy for hepatic graft-versus-host disease resembling acute hepatitis. Transplant Proc 2007; 39: 1710-1713.
306. Fang B, Song Y, Lin Q, et al. Human adipose tissue-derived mes-enchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children. Pediatr Transplant 2007; 11: 814-817.
307. Fang B, Song Y, Liao L, Zhang Y, Zhao RC. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proc 2007; 39: 3358-3362.
308. Augello A, Tasso R, Negrini SM, Cancedda R, Pennesi G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 2007; 56: 1175-1186.
309. Djouad F, Fritz V, Apparailly F, et al. Reversal of the immunosup-pressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 2005; 52: 1595-1603.
310. Zheng ZH, Li XY, Ding J, Jia JF, Zhu P. Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis. Rheumatology 2008; 47: 22-30.
311. Chen FH, Tuan RS. Mesenchymal stem cells in arthritic diseases. Arthritis Res Ther 2008; 10: 223.
312. Jorgensen C, Djouad F, Fritz V, Apparailly F, Plence P, Noel D. Mesenchymal stem cells and rheumatoid arthritis. Joint Bone Spine 2003; 70: 483-485.
313. Jorgensen C, Djouad F, Bouffi C, Mrugala D, Noel D. Multipotent mesenchymal stromal cells in articular diseases. Best Pract Res Clin Rheumatol 2008; 22: 269-284.
314. Djouad F, Bouffi C, Ghannam S, Noel D, Jorgensen C. Mesen-chymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol 2009; 5: 392-399.
315. Bouffi C, Djouad F, Mathieu M, Noel D, Jorgensen C. Multipotent mesenchymal stromal cells and rheumatoid arthritis: risk or benefit? Rheumatology (Oxford) 2009; 48: 1185-1189.
316. Kastrinaki MC, Papadaki HA. Mesenchymal stromal cells in rheumatoid arthritis: biological properties and clinical applications. Curr Stem Cell Res Ther 2009; 4: 61-69.
317. Noth U, Rackwitz L, Steinert AF, Tuan RS. Cell delivery therapeutics for musculoskeletal regeneration. Adv Drug Deliv Rev 2010; 62: 765-783.
318. Maumus M, Guerit D, Toupet K, Jorgensen C, Noel D. Mesen-chymal stem cell-based therapies in regenerative medicine: applications in rheumatology. Stem Cell Res Ther 2011; 2: 14.
319. Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 2009; 60: 1006-1019.
320. Grigolo B, Lisignoli G, Desando G, et al. Osteoarthritis treated with mesenchymal stem cells on hyaluronan-based scaffold in rabbit. Tissue Eng Part C Methods 2009; 15: 647-658.
321. Noth U, Steinert AF, Tuan RS. Technology insight: adult mesen-chymal stem cells for osteoarthritis therapy. Nat Clin Pract Rheu-matol 2008; 4: 371-380.
322. Davatchi F, Abdollahi BS, Mohyeddin M, Shahram F, Nikbin B. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int J Rheum Dis 2011; 14: 211-215.
323. Jorgensen C, Gordeladze J, Noel D. Tissue engineering through autologous mesenchymal stem cells. Curr Opin Biotechnol 2004; 15: 406-410.
324. Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002; 99: 8932-8937.
325. Quarto R, Mastrogiacomo M, Cancedda R, et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med 2001; 344: 385-386.
326. Lisignoli G, Fini M, Giavaresi G, Nicoli AN, Toneguzzi S, Fac-chini A. Osteogenesis of large segmental radius defects enhanced by basic fibroblast growth factor activated bone marrow stromal cells grown on non-woven hyaluronic acid-based polymer scaffold. Biomaterials 2002; 23: 1043-1051.
327. Hernigou P, Poignard A, Beaujean F, Rouard H. Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am 2005; 87: 1430-1437.
328. Marcacci M, Kon E, Moukhachev V, et al. Stem cells associated with macroporous bioceramics for long bone repair: 6- to 7-year outcome of a pilot clinical study. Tissue Eng 2007; 13: 947-955.
329. Berner A, Reichert JC, Muller MB, et al. Treatment of long bone defects and non-unions: from research to clinical practice. Cell Tissue Res 2011.
330. Meijer GJ, de Bruijn JD, Koole R, van Blitterswijk CA. Cell based bone tissue engineering in jaw defects. Biomaterials 2008; 29: 3053-3061.
331. Leucht P, Kim JB, Amasha R, James AW, Girod S, Helms JA. Embryonic origin and Hox status determine progenitor cell fate during adult bone regeneration. Development 2008; 135: 2845-2854.
332. Rehman J, Traktuev D, Li J, et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004; 109: 1292-1298.
333. De Francesco F, Tirino V, Desiderio V, et al. Human CD34/CD90 ASCs are capable of growing as sphere clusters, producing high levels of VEGF and forming capillaries. PLoS One 2009; 4: e6537.
334. Mesimaki K, Lindroos B, Tornwall J, et al. Novel maxillary reconstruction with ectopic bone formation by GMP adipose stem cells. Int J Oral Maxillofac Surg 2009; 38: 201-209.
335. Thesleff T, Lehtimaki K, Niskakangas T, et al. Cranioplasty with adipose-derived stem cells and biomaterial. A novel method for cranial reconstruction. Neurosurgery 2011.
336. Trebol LJ, Georgiev HT, Garcia-Arranz M, Garcia-Olmo D. Stem cell therapy for digestive tract diseases: current state and future perspectives. Stem Cells Dev 2011, e-pub.
337. Duijvestein M, Vos AC, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory lu-minal Crohn's disease: results of a phase I study. Gut 2010; 59: 1662-1669.
338. Ko IK, Kim BG, Awadallah A, et al. Targeting improves MSC treatment of inflammatory bowel disease. Mol Ther 2010; 18: 1365-1372.
339. Allison M. Genzyme backs Osiris, despite Prochymal flop. Nat Biotechnol 2009; 27: 966-967.
340. Gonzalez-Rey E, Anderson P, Gonzalez MA, Rico L, Buscher D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009; 58: 929-9239.
341. Garcia-Olmo D, Garcia-Arranz M, Garcia LG, et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn's disease: a new cell-based therapy. Int J Colorectal Dis 2003; 18: 451-454.
342. Garcia-Olmo D, Herreros D, Pascual M, et al. Treatment of entero-cutaneous fistula in Crohn's Disease with adipose-derived stem cells: a comparison of protocols with and without cell expansion. Int J Colorectal Dis 2009; 24: 27-30.
343. Garcia-Olmo D, Garcia-Arranz M, Herreros D. Expanded adipose-derived stem cells for the treatment of complex perianal fistula including Crohn's disease. Expert Opin Biol Ther 2008; 8: 1417-1423.
344. Taxonera C, Schwartz DA, Garcia-Olmo D. Emerging treatments for complex perianal fistula in Crohn's disease. World J Gastroen-terol 2009; 15: 4263-4272.
345. Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fis-tulising Crohn's disease. Gut 2011; 60: 788-798.
346. Chamberlain J, Yamagami T, Colletti E, et al. Efficient generation of human hepatocytes by the intrahepatic delivery of clonal human mesenchymal stem cells in fetal sheep. Hepatology 2007; 46: 1935-1945.
347. Wang J, Bian C, Liao L, et al. Inhibition of hepatic stellate cells proliferation by mesenchymal stem cells and the possible mechanisms. Hepatol Res 2009; 39: 1219-1228.
348. Li TZ, Kim JH, Cho HH, et al. Therapeutic potential of bone-marrow-derived mesenchymal stem cells differentiated with growth-factor-free coculture method in liver-injured rats. Tissue Eng Part A 2010; 16: 2649-59.
349. Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, et al. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med 2007; 10: 459-466.
350. Lyra AC, Soares MB, da Silva LF, et al. Infusion of autologous bone marrow mononuclear cells through hepatic artery results in a short-term improvement of liver function in patients with chronic liver disease: a pilot randomized controlled study. Eur J Gastroen-terol Hepatol 2010; 22: 33-42.
351. Kharaziha P, Hellstrom PM, Noorinayer B, et al. Improvement of liver function in liver cirrhosis patients after autologous mesen-chymal stem cell injection: a phase I-II clinical trial. Eur J Gastro-enterol Hepatol 2009; 21: 1199-1205.
352. Ezquer FE, Ezquer ME, Parrau DB, Carpio D, Yanez AJ, Conget PA. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant 2008; 14: 631-640.
353. Urban VS, Kiss J, Kovacs J, et al. Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. Stem Cells 2008; 26: 244-653.
354. Rackham CL, Chagastelles PC, Nardi NB, Hauge-Evans AC, Jones PM, King AJ. Co-transplantation of mesenchymal stem cells maintains islet organisation and morphology in mice. Diabetologia 2011; 54: 1127-1135.
355. Bell GI, Broughton HC, Levac KD, Allan DA, Xenocostas A, Hess DA. Transplanted human bone marrow progenitor subtypes stimulate endogenous islet regeneration and revascularization. Stem Cells Dev 2011.
356. Xie QP, Huang H, Xu B, et al. Human bone marrow mesenchymal stem cells differentiate into insulin-producing cells upon microen-vironmental manipulation in vitro. Differentiation 2009; 77: 483-491.
357. Park KS, Kim YS, Kim JH, et al. Trophic molecules derived from human mesenchymal stem cells enhance survival, function, and an-giogenesis of isolated islets after transplantation. Transplantation 2010; 89: 509-517.
358. Trivedi HL, Vanikar AV, Thakker U, et al. Human adipose tissue-derived mesenchymal stem cells combined with hematopoietic stem cell transplantation synthesize insulin. Transplant Proc 2008; 40: 1135-1139.
359. Vanikar AV, Dave SD, Thakkar UG, Trivedi HL. Cotransplanta-tion of adipose tissue-derived insulin-secreting mesenchymal stem cells and hematopoietic stem cells: a novel therapy for insulin-dependent diabetes mellitus. Stem Cells Int 2010; 2010: 582382.
360. Sanz-Ruiz R, Gutierrez IE, Arranz AV, Fernandez Santos ME, Fernandez PL, Fernandez-Aviles F. Phases I-III Clinical Trials Using Adult Stem Cells. Stem Cells Int 2010; 2010: 579142.
361. Choi YH, Kurtz A, Stamm C. Mesenchymal stem cells for cardiac cell therapy. Hum Gene Ther 2011; 22: 3-17.
362. Chin SP, Poey AC, Wong CY, et al. Intramyocardial and intra-coronary autologous bone marrow-derived mesenchymal stromal cell treatment in chronic severe dilated cardiomyopathy. Cytother-apy 2011, e-pub.
363. Katritsis DG, Sotiropoulou P, Giazitzoglou E, Karvouni E, Papa-michail M. Electrophysiological effects of intracoronary transplantation of autologous mesenchymal and endothelial progenitor cells. Europace 2007; 9: 167-171.
364. Guo J, Lin GS, Bao CY, Hu ZM, Hu MY. Anti-inflammation role for mesenchymal stem cells transplantation in myocardial infarction. Inflammation 2007; 30: 97-104.
365. Peran M, Marchal JA, Lopez E, et al. Human cardiac tissue induces transdifferentiation of adult stem cells towards cardiomyocytes. Cytotherapy 2010; 12: 332-337.
366. Chen SL, Fang WW, Ye F, et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mes-enchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004; 94: 92-95.
367. Chen S, Liu Z, Tian N, et al. Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic car-diomyopathy due to isolated chronic occluded left anterior descending artery. J Invasive Cardiol 2006; 18: 552-556.
368. Yang Z, Zhang F, Ma W, et al. A novel approach to transplanting bone marrow stem cells to repair human myocardial infarction: delivery via a noninfarct-relative artery. Cardiovasc Ther 2010; 28: 380-385.
369. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myo-cardial infarction. J Am Coll Cardiol 2009; 54: 2277-2286.
370. Lasala GP, Minguell JJ. Vascular disease and stem cell therapies. Br Med Bull 2011; 98: 187-197.
371. Prochazka V, Gumulec J, Jaluvka F, et al. Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer. Cell Transplant 2010; 19: 1413-1424.
372. Sadan O, Melamed E, Offen D. Bone-marrow-derived mesenchy-mal stem cell therapy for neurodegenerative diseases. Expert Opin Biol Ther 2009; 9: 1487-1497.
373. Joyce N, Annett G, Wirthlin L, Olson S, Bauer G, Nolta JA. Mes-enchymal stem cells for the treatment of neurodegenerative disease. Regen Med 2010; 5: 933-946.
374. Wright KT, El Masri W., Osman A, Chowdhury J, Johnson WE. Bone Marrow for the Treatment of Spinal Cord Injury: Mechanisms and Clinical Application. Stem Cells 2011; 29: 169-178.
375. Park HJ, Lee PH, Bang OY, Lee G, Ahn YH. Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease. J Neurochem 2008; 107: 141-151.
376. Choi MR, Kim HY, Park JY, et al. Selection of optimal passage of bone marrow-derived mesenchymal stem cells for stem cell therapy in patients with amyotrophic lateral sclerosis. Neurosci Lett 2010; 472: 94-98.
377. Lee PH, Park HJ. Bone marrow-derived mesenchymal stem cell therapy as a candidate disease-modifying strategy in Parkinson's disease and multiple system atrophy. J Clin Neurol 2009; 5: 1-10.
378. Bianco P, Gehron RP. Marrow stromal stem cells. J Clin Invest 2000; 105: 1663-1668.
379. Zipori D. The stem state: plasticity is essential, whereas self-renewal and hierarchy are optional. Stem Cells 2005; 23: 719-726.
380. Gimble JM, Zvonic S, Floyd ZE, Kassem M, Nuttall ME. Playing with bone and fat. J Cell Biochem 2006; 98: 251-266.
381. Krinner A, Hoffmann M, Loeffler M, Drasdo D, Galle J. Individual fates of mesenchymal stem cells in vitro. BMC Syst Biol 2010; 4: 73.
382. Charbord P, Livne E, Gross G, et al. Human bone marrow mesen-chymal stem cells: a systematic reappraisal via the genostem experience. Stem Cell Rev 2011; 7: 32-42.
383. Pevsner-Fischer M, Levin S, Zipori D. The origins of mesenchymal stromal cell heterogeneity. Stem Cell Rev 2011; 7: 560-568.
384. Ponce ML, Koelling S, Kluever A, et al. Coexpression of os-teogenic and adipogenic differentiation markers in selected sub-populations of primary human mesenchymal progenitor cells. J Cell Biochem 2008; 104: 1342-1355.
385. Song L, Tuan RS. Transdifferentiation potential of human mesen-chymal stem cells derived from bone marrow. FASEB J 2004; 18: 980-982.
386. Oreffo RO, Cooper C, Mason C, Clements M. Mesenchymal stem cells: lineage, plasticity, and skeletal therapeutic potential. Stem Cell Rev 2005; 1: 169-178.
387. Custer RP, Ahfeldt FE. Studies on the structure and function of bone marrow. II. Variations in cellularity in various bones with advancing years of life and their relative response to stimuli. J Lab Clin Med 1932; 17: 960-962.
388. Vost A. Osteoporosis: a necropsy study of vertebrae and iliac crests. Am J Pathol 1963; 43: 143-151.
389. Hartsock RJ, Smith EB, Petty CS. Normal variations with aging of the amount of hematopoietic tissue in bone marrow from the anterior iliac crest. A study made from 177 cases of sudden death examined by necropsy. Am J Clin Pathol 1965; 43: 326-331.
390. Rubin H. Promise and problems in relating cellular senescence in vitro to aging in vivo. Arch Gerontol Geriatr 2002; 34: 275-286.
391. Mareschi K, Ferrero I, Rustichelli D, et al. Expansion of mesen-chymal stem cells isolated from pediatric and adult donor bone marrow. J Cell Biochem 2006; 97: 744-754.
392. Wilson A, Shehadeh LA, Yu H, Webster KA. Age-related molecular genetic changes of murine bone marrow mesenchymal stem cells. BMC Genomics 2010; 11: 229.
393. Makhluf HA, Mueller SM, Mizuno S, Glowacki J. Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges. Bio-chem.Biophys.Res.Commun. 2000; 268: 669-672.
394. Mueller SM, Glowacki J. Age-related decline in the osteogenic potential of human bone marrow cells cultured in three-dimensional collagen sponges. J Cell Biochem 2001; 82: 583-590.